Zenith Capital Corp. (ZHCLF)

0.2000 0.0000 (0.00%) At close: 02:27PM EDT

Zenith Capital Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1
Canada
587 390 7865
https://www.zenithepigenetics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Donald J. McCaffrey	Chairman, President & CEO	98.58k	N/A	N/A
Mr. Aaron Bradley Cann C.A., CPA, CBV	CFO & Secretary	42.31k	N/A	N/A
Dr. Sanjay Lakhotia M.B.A., Ph.D.	Chief Business Officer	315.44k	N/A	N/A
Dr. Henrik Claus Hansen Ph.D.	Senior Vice President of Operations	232.96k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer, as well as advanced or metastatic triple negative breast cancer in collaboration with Pfizer Inc. The company has research and development collaboration agreement with National Cancer Institute, and licensing agreement with Newsoara to develop ZEN-3694, as well as with University of California. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. The company was incorporated in 2013 and is headquartered in Calgary, Canada.

Corporate governance

Zenith Capital Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.